Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01191060 |
|
Recruitment Status :
Completed
First Posted : August 30, 2010
Last Update Posted : April 18, 2019
|
Sponsor:
University Hospital, Toulouse
Collaborators:
Dana-Farber Cancer Institute
Celgene Corporation
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
University Hospital, Toulouse
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Objective of this study is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. HDT as compared to conventional dose treatment would be considered superior if it significantly prolongs Progression-free survival (by at least 9 months).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Myeloma | Drug: Lenalidomide, Bortezomib | Phase 3 |
Study design Phase III, multicenter, randomized, open-label study designed to evaluate the clinical benefit from the drug combination RVD without immediate high-dose therapy (HDT) followed by lenalidomide maintenance (Arm A) versus RVD plus HDT and PBSCT followed by lenalidomide maintenance (Arm B).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 700 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age |
| Actual Study Start Date : | October 2010 |
| Actual Primary Completion Date : | November 30, 2018 |
| Actual Study Completion Date : | November 30, 2018 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Multiple myeloma
MedlinePlus related topics:
Multiple Myeloma
| Arm | Intervention/treatment |
|---|---|
|
Experimental: lenalidomide, bortezomib with ASCT
RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) Autologous stem cell transplant: Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months) |
Drug: Lenalidomide, Bortezomib
Lenalidomide Bortezomib Dexamethasone cycles: Number of cycles: 5 cycles for arm B Cycle length Dosage:
Maintenance phase (12 months): Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed Other Names:
|
|
Experimental: lenalidomide, bortezomib without ASCT
RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
|
Drug: Lenalidomide, Bortezomib
Lenalidomide/Bortézomib/Dexamethasone cycles: Number of cycles: 8 cycles for arm A Cycle length Dosage:
Maintenance phase (12 months): Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed Other Names:
|
Primary Outcome Measures :
- Progression Free Survival [ Time Frame: up to 4 years ]To compare progression-free survival (PFS) between the Arm A and Arm B up to 4 years or until progression
Secondary Outcome Measures :
- Response Rates [ Time Frame: up to 4 years ]-Response rates (RR) between the two arms up to 4 years or until progression
- Time To Progression [ Time Frame: up to 4 years ]Time to progression (TTP) between the two arms up to 4 years or until progression
- Toxicity comparison [ Time Frame: up to 4 years ]Toxicity comparison between the two arms randomization up to 4 years or until progression
- Genetic prognostic groups definition [ Time Frame: up to 4 years ]Genetic prognostic groups definition (evaluated by gene expression profiling-GEP) from randomization up to 4 years or until progression
- Best treatment examination in each GEP-defined prognostic group. [ Time Frame: up to 4 years ]Best treatment examination in each GEP-defined prognostic group. from randomization up to 4 years or until progression
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria for registration :
(with labs performed within 21 days of initiation of protocol therapy):
- Patients diagnosed with multiple myeloma based on International Myeloma Foundation 2003 Diagnostic Criteria.
- Patients must have symptomatic myeloma with myeloma-related organ damage.
- Patients must have myeloma that is measurable by either serum or urine evaluation of the monoclonal component or by assay of serum free light chains.
- Age between 18 and 65 years at the time of signing the informed consent document.
- ECOG performance status <2 (Karnofsky ≥ 60%)
- Negative HIV blood test
Exclusion Criteria for registration (section 4.2):
- Participants must not have been treated with any prior systemic therapy for multiple myeloma. Treatment by localized radiotherapy is not an exclusion criterion if an interval of at least two weeks between the end of radiotherapy and initiation of protocol therapy entry in the study is observed. Similarly, the dose of corticosteroids received by the participant should not exceed the equivalent of 160 mg of dexamethasone over a two-week period before initiation of protocol therapy.
- Primary amyloidosis (AL) or myeloma complicated by amylosis.
- Participants may not be receiving any other study investigational agents.
- Participants with known brain metastases
- Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to study agents
- Platelet count < 50,000/mm3 per µLwithin 21 days of initiation of protocol therapy. Transfusion within 7 days of screening is not allowed to meet platelet eligibility criteria.
- ANC < 1,000 cells/mm3 within 21 days of initiation of protocol therapy. Growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria.
- Hemoglobin < 8.0 g/dL within 21 days of initiation of protocol therapy. Transfusion may be used to meet hemoglobin eligibility criteria.
- Hepatic impairment, defined a bilirubin > 1.5 x institutional upper limit of normal (ULN) > 2 mg/dL (Patients with benign hyperbilirubinemia (e.g., Gilbert's syndrome) are eligible) and or AST (SGOT), or ALT (SGPT), or alkaline phosphatase > 2 x ULN
- Renal insufficiency, defined as serum creatinine > 2.5 mg/dl and/or creatinine clearance < <40 60 ml/min (actual or calculated). The Cockgroft-Gault formula should be used for calculating creatinine clearance values, and may be located in Section 4.2
- Respiratory compromise, defined as ventilation tests and with DLCO < 50%
- Participant must not demonstrate with clinical signs of heart or coronary failure, or evidence of LVEF < 40%. Participant must not have with myocardial infarction within 6 months prior to enrollment or have New York Heart Association (NYHA Appendix VII) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.
- Intercurrent illness including, but not limited to ongoing or active severe infection, known (active or not) infection with hepatitis B or C virus, poorly controlled diabetes, severe uncontrolled psychiatric disorder or psychiatric illness/social situations that would limit compliance with study requirements.
- Participant with previous history of another malignant condition, except for basal cell carcinoma and stage I cervical cancer
- Female participant who is pregnant or breast-feeding
- Inability to comply with an anti-thrombotic treatment regimen
- Peripheral neuropathy ≥ Grade 2 peripheral neuropathy on clinical examination within 21 days of initiation of protocol therapy
- Mental illness likely to interfere with participation in the study and Adults under juridical protection
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01191060
Locations
Show 68 study locations
Sponsors and Collaborators
University Hospital, Toulouse
Dana-Farber Cancer Institute
Celgene Corporation
Janssen-Cilag Ltd.
Investigators
| Principal Investigator: | MICHEL ATTAL, MD PhD | University Hospital of Toulouse |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University Hospital, Toulouse |
| ClinicalTrials.gov Identifier: | NCT01191060 |
| Other Study ID Numbers: |
09 110 01 |
| First Posted: | August 30, 2010 Key Record Dates |
| Last Update Posted: | April 18, 2019 |
| Last Verified: | April 2019 |
Keywords provided by University Hospital, Toulouse:
|
Progression free survival prolongation Disease Progression Overall survival |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders |
Immunoproliferative Disorders Immune System Diseases Lenalidomide Bortezomib Immunologic Factors Physiological Effects of Drugs Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors Antineoplastic Agents |